News

Keep up with the latest news from the NCI Center for Biomedical Informatics and Information Technology (CBIIT) and the data science communities.

An NCI-funded technology blends specific molecular markers along with traditional morphological features in the same cells and in one digital slide. This tool could someday help pathologists and ML models better predict cancer treatment response and outcomes.

An international team of researchers combined genomics, biopsy results, and artificial intelligence (AI) to track prostate cancer over time. Learn more about these “evolvability” metrics and how they could someday help predict cancer re-occurrence.

NCI-funded researchers are blending mathematics with machine learning to refine cancer treatment. In the future, this kind of virtual tumor model could help to further personalize care for people with cancer.

NCI researchers are using artificial intelligence (AI) to uncover additional information from medical images. This helps them not only to diagnose cancer but also to predict how it will progress and if it will re-occur.

A new, scalable, machine learning model is helping scientists model thousands of transcription factors and genes in the human genome, providing new information on these genes and how they work/change over time.

With the help of machine learning, NCI-funded researchers were able to boost the prognostic power of a common blood test for liver cancer.

Interpreting whole slide images can be a labor intensive and difficult task. A recent article describes a new approach that helps classify cancer and predict how it will progress.

In the study, artificial intelligence (AI)-assisted contours outperformed manual contours, indicating the technology’s potential to enhance treatment strategies and improve outcomes for patients.

Discover a new AI-driven tool that uses single-cell RNA data to help predict patient responses to cancer treatments.

NCI-funded researchers used machine learning to characterize a cancer biomarker based on exosomes. Their biomarker worked well using non-invasive sources, such as blood and urine, allowing the researchers to catch cancer early, even in tumors of undetermined origins.